Shares of AstraZeneca PLC AZN inched up 0.05% to £110.46 Thursday, on what proved to be an all-around positive trading ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

AstraZeneca will invest 820 million Canadian dollars, equivalent to $570.3 million, to facilitate a move to a larger office in the Toronto metro area. The Anglo-Swedish pharmaceutical giant said ...

AstraZeneca is expanding its boot print in Canada with a $570 million investment designed to create 700 jobs. | AstraZeneca is expanding its boot print in Canada with a $570 million investment ...

U.K. pharmaceutical company says Canadian presence will contribute to its goal of bringing 20 new medicines to market by 2030 ...

AstraZeneca announced a new investment in Canada to support the company’s move into a larger, more modern facility in Greater Toronto Area.

AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...

Invest Ontario is partnering with AstraZeneca (AZN) to expand the company’s global R&D hub in Mississauga. This $820M investment ...

The approval of Calquence marks the first and only BTK inhibitor approved for the first-line treatment of MCL in the US.